Gardasil again denied approval for women 27-45

The Vancouver Sun

February 13, 2010

NEW YORK (Reuters) – U.S. health regulators have again withheld approval for the use of Merck & Co Inc’s Gardasil cervical cancer vaccine by women aged 27 to 45, asking for longer-term clinical data, the drugmaker said on Friday.

The U.S. Food and Drug Administration recommended Merck submit data when a 48-month study on a test group has been completed. The agency also withheld approval in June on Merck’s initial application that was based on data collected through an average of 24 months.

Merck shares fell nearly 3 percent in midday trading.

Gardasil, one of Merck’s most successful newer products, was approved in 2006 for preventing cervical cancer and genital warts in females between the ages of 9 and 26.

It works by preventing infection with the sexually transmitted human papillomavirus (HPV), which causes cervical cancer.

“Gardasil’s efficacy drops sharply once females have been exposed to HPV and this is probably the genesis of the problem with the older female population that Merck has been pushing for in this new application,” Sanford Bernstein analyst Tim Anderson said in a research note.

Moreover, because effectiveness is naturally lower in older females, Merck could have difficulty convincing insurers to cover Gardasil in that group should it be approved for them, Anderson added.

The FDA letter does not affect the use of the drug in the approved age group, or Merck’s recently filed application to expand use to males, the company said. By preventing infection among males, the hope is they would not be able to spread the virus to females through sexual contact.



Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.